Debt-to-equity of NovaBay Pharmaceuticals, Inc. from 30 Sep 2018 to 30 Sep 2025

Taxonomy & unit: ratio: %
Description: Debt-to-equity (D/E) ratio is used to evaluate a company's financial leverage and is calculated by dividing a company's total liabilities by its shareholder equity.
Summary: NovaBay Pharmaceuticals, Inc. quarterly Debt-to-equity in % history and change rate from 30 Sep 2018 to 30 Sep 2025.
NovaBay Pharmaceuticals, Inc. Debt-to-equity for the quarter ending 30 Sep 2025 was 103%, a 78% decline year-over-year.

Debt-to-equity, Quarterly (%)

Debt-to-equity, YoY Quarterly Change (%)

NovaBay Pharmaceuticals, Inc. Quarterly Debt-to-equity (%)

Period	Value	YoY Chg	Change %	Date
Q3 2025	103%	-361%	-78%	30 Sep 2025
Q2 2025	112%	-103%	-48%	30 Jun 2025
Q1 2025	225%	+98%	+77%	31 Mar 2025
Q4 2024	3312%	+3222%	+3596%	31 Dec 2024
Q3 2024	465%	+393%	+551%	30 Sep 2024
Q2 2024	215%	+148%	+223%	30 Jun 2024
Q1 2024	127%	+73%	+137%	31 Mar 2024
Q4 2023	90%	+42%	+90%	31 Dec 2023
Q3 2023	71%	+10%	+16%	30 Sep 2023
Q2 2023	67%	+11%	+20%	30 Jun 2023
Q1 2023	53%	-0.44%	-0.82%	31 Mar 2023
Q4 2022	47%	-5.9%	-11%	31 Dec 2022
Q3 2022	61%	+36%	+139%	30 Sep 2022
Q2 2022	56%	+32%	+132%	30 Jun 2022
Q1 2022	54%	-2.4%	-4.4%	31 Mar 2022
Q4 2021	53%	-52%	-50%	31 Dec 2021
Q3 2021	26%	-204%	-89%	30 Sep 2021
Q2 2021	24%	-935%	-98%	30 Jun 2021
Q1 2021	56%	-698%	-93%	31 Mar 2021
Q4 2020	105%	-464%	-82%	31 Dec 2020
Q3 2020	230%	-73%	-24%	30 Sep 2020
Q2 2020	959%	+775%	+419%	30 Jun 2020
Q1 2020	755%	+644%	+584%	31 Mar 2020
Q4 2019	570%	+504%	+767%	31 Dec 2019
Q3 2019	303%	+218%	+259%	30 Sep 2019
Q2 2019	185%			30 Jun 2019
Q1 2019	110%			31 Mar 2019
Q4 2018	66%			31 Dec 2018
Q3 2018	84%			30 Sep 2018

* An asterisk sign (*) next to the value indicates that the value is likely invalid.